Business
Creative Medical is developing stem-cell and immune-cell programs through subsidiaries and platforms including ImmCelz, StemSpine, AlloStem, and iPScelz.
Creative Medical remains a tiny-revenue stem-cell developer with widening losses, negative cash flow, and weak earnings quality.
The read at a glance✓ Audited against SEC data
- Business mix — Stem-cell therapeuticsNote
- Revenue — $6,000, -45.5%Watch
- Net loss — ($6.0M)Watch
- Cash flow — OCF ($5.9M)Watch
- Equity — $7.5M, +18.5%Note
- Insiders — 0 purchases and 0 salesNote
- Accounting — Altman grey; Beneish N/A; EQ weakWatch
Latest filings
- 8-K · Company announcement2026-08-31
- 10-Q · Quarterly report2026-08-07
- DEF 14A · Annual proxy (pay & governance)2026-07-14
- 8-K · Company announcement2026-07-02
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.